What is claimed is:

1. A lung surfactant composition comprising:

a. a polypeptide comprising a surfactant B protein N-terminal domain (SP-BN); and

b. at least one phospholipid.

2. The lung surfactant composition of claim **1**, wherein the polypeptide further comprises a surfactant B protein middle domain (SP-BM) and/or surfactant B protein C-terminal domain (SP-BC).

3. A lung surfactant composition comprising:

a. a polypeptide comprising a surfactant B protein middle domain (SP-BM); and

b. at least one phospholipid

4. The lung surfactant composition of claim **3**, wherein the polypeptide lacks a surfactant B protein N-terminal domain (SP-BN) and/or a surfactant B protein C-terminal domain (SP-BC).

5. The lung surfactant composition of claim **1**, wherein the phospholipid is a glycerophospholipid.

6. The lung surfactant composition of claim **1**, wherein the phospholipid is selected from the group consisting of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC); phosphatidylglycerol (PG); phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), and phosphatidylinositol (PI).

7. The lung surfactant composition of claim **1**, wherein the phospholipid is DPPC, PG, or a combination thereof.

8. The lung surfactant composition of claim **1**, wherein the SP-BN is human, bovine, or mouse SP-BN.

9. The lung surfactant composition of claim **2**, wherein the SP-BM is human, bovine, or mouse SP-BM.

10. The lung surfactant composition of claim **1**, wherein the composition is formulated with a pharmaceutically acceptable carrier.

11. The lung surfactant composition of claim **1**, wherein the composition is formulated for intratracheal delivery.

12. The lung surfactant composition of claim **1**, further comprising a Surfactant Protein C (SP-C) or a fragment thereof; and/or an additional lung surfactant.

13. The lung surfactant composition of claim **1**, wherein the SP-BN, the SP-BM, or the SP-BC comprises one or more amino acid substitutions or mutations.

14. The lung surfactant composition of claim **13**, wherein the SP-BM comprises a $C_{48}\Delta$ amino acid substitution.

15. The lung surfactant composition of claim **13**, wherein the SP-BN comprises a K46E, P50C, R51E, Y59A, and/or a H79Δ amino acid substitution, or any combination thereof.

16. A fusion protein comprising:

i. a peptide tag;

ii. a surfactant B protein N-terminal domain (SP-BN);

iii. a linker; and

iv. a surfactant B protein middle domain (SP-BM) domain.

17. The fusion protein of claim **16**, where the linker comprises a cleavage site.

18. The fusion protein of claim **16**, wherein cleavage site is a protease cleavage site.

19. The fusion protein of claim **16**, wherein the fusion protein lacks a surfactant B protein C-terminal domain (SP-BC).

20. The fusion protein of claim **16**, wherein the fusion protein further comprises a saposin polypeptide between the peptide tag and the SP-BN domain.

* * * * *